Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine, Inc. (Nasdaq: EDIT) is a clinical-stage gene editing company that regularly issues news and updates about its in vivo CRISPR-based pipeline. Company announcements emphasize the development of transformative in vivo medicines using CRISPR/Cas12a and CRISPR/Cas9 systems, proprietary targeted lipid nanoparticle delivery, and a differentiated gene upregulation strategy applied to serious diseases.
News about Editas Medicine frequently covers progress with its lead in vivo development candidate, EDIT-401, an LDLR-targeted gene editing medicine designed to treat hyperlipidemia by increasing LDL receptor expression and reducing LDL cholesterol (LDL-C) levels. Recent releases have described preclinical proof-of-concept data in non-human primates and mice, showing approximately 90% or greater reductions in LDL-C after a single dose, as well as presentations at major scientific meetings such as the European Society of Gene and Cell Therapy Congress and the American Heart Association Scientific Sessions.
Investors and followers of EDIT can also expect updates on Editas’ in vivo hematopoietic stem cell program for sickle cell disease and beta thalassemia, including data on HBG1/2 promoter editing, fetal hemoglobin upregulation, and targeted lipid nanoparticle delivery in humanized mice and non-human primates. Additional news items highlight in vivo proof-of-concept for undisclosed liver targets, conference presentations at ASGCT, EHA, and TIDES, and participation in healthcare and investor conferences.
Financial news from Editas Medicine includes quarterly results, collaboration milestones such as the CD19 HD allogeneic CAR T program with Bristol Myers Squibb, and updates on cash runway supported by cash, marketable securities, at-the-market equity proceeds, and payments under its license agreement with Vertex Pharmaceuticals. This news page helps readers follow how scientific data, regulatory plans, collaborations, and financial developments shape the EDIT investment story over time.
Editas Medicine (Nasdaq: EDIT) reported third quarter 2025 results and business updates on Nov 10, 2025. Key highlights include preclinical data showing ≥90% LDL-C reduction in non-human primates within 48 hours after a single dose of EDIT-401, durable LDL-C lowering in mice, and a mean ≥6-fold increase in liver LDLR protein. The company remains on track to submit an IND/CTA for EDIT-401 by mid-2026 and target initial human proof-of-concept by year-end 2026. Financially, cash and marketable securities were $165.6M as of Sept 30, 2025, cash runway extended into Q3 2027, Q3 net loss was $25.1M, and Q3 collaboration revenue rose to $7.5M.
Editas Medicine (Nasdaq: EDIT) announced a moderated digital poster presentation at the American Heart Association Scientific Sessions 2025 in New Orleans, Nov 7–10, 2025. The poster, titled “A transformative LDL cholesterol–lowering in vivo CRISPR gene editing medicine that functionally upregulates LDLR in mice and non-human primates”, is scheduled for Saturday, November 8, 10:45 a.m.–11:45 a.m. CT in the Basic Science Zone during the session Cutting-Edge Gene and Precision Therapies. Presenter: Anshul Gupta, Vice President, Preclinical Development. Final abstract number is 4364195. The accepted abstract is available on the AHA website and a copy of the poster will be posted in the company’s Posters & Presentations web section at the time of the presentation and remain accessible afterwards.
Editas Medicine (NASDAQ: EDIT) reported in vivo preclinical proof-of-concept data for EDIT-401 on October 9, 2025, showing robust LDL-cholesterol lowering in animal models.
Key readouts: ≥90% mean LDL-C reduction in non-human primates within 48 hours and in mice with high baseline LDL-C; a ≥6-fold mean increase in LDLR protein in NHP liver; LDL-C reductions were durable in a three-month mouse study. Data were presented at the ESGCT 32nd Annual Congress and will be posted on the company website.
Editas Medicine (Nasdaq: EDIT) announced an oral presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress in Seville, Spain, Oct 7–10, 2025.
Presentation: “A transformative LDL‑cholesterol–lowering in vivo CRISPR gene editing medicine that functionally upregulates LDLR in mice and non‑human primates.”
Presenter: Linda Burkly, Ph.D., Executive VP & Chief Scientific Officer. Session: Gene Editing II, Ex Vivo Applications on Thursday, Oct 9 at 5:00 p.m. CEST / 11:00 a.m. ET. Final Abstract No. OR069. Abstracts are available to registrants.
Management will also appear at two investor events in October: H.C. Wainwright Genetic Medicines Virtual Conference (fireside chat, Oct 14) and Chardan 9th Annual Genetic Medicines Conference panel (Oct 21, New York). Live webcasts and archived replays will be available in the company Investors section for about 30 days.
Editas Medicine (Nasdaq: EDIT) has nominated EDIT-401 as its lead in vivo development candidate, marking a significant milestone in gene editing therapeutics. This experimental therapy aims to reduce LDL cholesterol levels through a one-time treatment, achieving approximately 90% mean LDL-C reduction in non-human primate studies.
The company expects to deliver human proof-of-concept data by the end of 2026 and maintains a strong financial position with operational runway extending into the second quarter of 2027. Editas will host a company-sponsored webinar today to discuss EDIT-401's development and potential.
Editas Medicine (Nasdaq: EDIT), a leading gene editing company, has scheduled a webinar for Tuesday, September 2, 2025, at 8:00 a.m. ET to announce their lead in vivo development candidate. The presentation will be accessible through a webcast link and the company's investor relations website.
The webinar will focus on revealing details about their latest advancement in gene editing technology aimed at developing transformative medicines for serious diseases. A replay will be available in the Investors section of the Editas Medicine website following the presentation.
Editas Medicine (NASDAQ: EDIT), a gene editing company, has announced its participation in three major healthcare investor conferences in September 2025. The company will attend the Wells Fargo Healthcare Conference on September 3 in Boston, the Cantor Global Healthcare Conference on September 4 in New York featuring a fireside chat at 11:30 a.m. ET, and the Baird Global Healthcare Conference on September 9 in New York.
Live webcasts of available presentations can be accessed through the Investors section of Editas Medicine's website, with replays available for approximately 30 days after each event.
[]Editas Medicine (Nasdaq: EDIT) reported Q2 2025 financial results and business updates. The company plans to select its first in vivo development candidate in September, targeting an IND filing by mid-2026 and human proof-of-concept by year-end 2026. Key highlights include the acceptance of first IND/CTA for CD19 HD Allo CAR T program with Bristol Myers Squibb and presentation of promising preclinical data at multiple scientific conferences.
Financial results show a net loss of $53.2 million ($0.63 per share), improved from $67.6 million loss in Q2 2024. The company maintains a strong cash position of $178.5 million, providing runway into Q2 2027. Research and development expenses decreased to $16.2 million from $54.2 million year-over-year, while restructuring charges were $26.1 million related to the discontinuation of the reni-cel program.
Editas Medicine (NASDAQ: EDIT) announced the acceptance of new preclinical data for presentation at the European Hematology Association (EHA) 2025 Congress in Milan. The study, conducted in non-human primates, demonstrates promising results for their in vivo hematopoietic stem cell (HSC) gene editing program targeting sickle cell disease and beta thalassemia.
Key findings include high-efficiency HSC delivery, therapeutically relevant editing levels in the HBG1/2 promoter region exceeding 25% threshold with a single dose, and favorable biodistribution using Editas' targeted lipid nanoparticle (tLNP) technology. The data shows significant liver de-targeting compared to standard LNPs, supporting further development of their proprietary HSC-tLNP platform.
FAQ
What is the current stock price of Editas Medicine (EDIT)?
What is the market cap of Editas Medicine (EDIT)?
